



#16  
BP  
3-12-c

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
Application of: Dasseux, et al.

Application No.: 09/465,718

Group Art Unit: 1631

Filed: December 17, 1999

Examiner: Borin

For: *Apolipoprotein A-I Agonists and  
Their Use to Treat Dyslipidemic Disorders*

Attorney Docket No.: 9196-018-999

TERMINAL DISCLAIMER

RECEIVED  
MAR 05 2002  
TECH CENTER 1600/2900

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Jean-Louis Dasseux, Renate Sekul, Klaus Büttner, Isabelle Cornut, Günther Metz, and Jean Dufourcq (hereinafter "Inventors"), represent that they are the owners of the above identified application and U.S. Patent Nos. **6,004,925; 6,037,323; and 6,265,377.**

The inventors hereby disclaim the terminal part of any patent granted on the above identified application which would extend beyond the expiration date of U.S. Patent Nos. **6,004,925; 6,037,323; and 6,265,377** and hereby agree that any patent so granted on the above identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to U.S. Patent Nos. **6,004,925; 6,037,323; and 6,265,377.**

The inventors further agree that this agreement is to run with any patent granted on the above identified application and is to be binding upon the grantee, its successors, and assigns.


The inventors do not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of U.S. Patent Nos. **6,004,925; 6,037,323; and 6,265,377** in the event that said patents later: expire for failure to pay a maintenance fee, are held unenforceable, are found invalid, are statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), have all claims canceled by a reexamination certificate, or are otherwise terminated prior to the expiration of their full statutory term, except for the separation of legal title stated above.

03/13/2002 WPHILLIP 00000001 161158 09465718  
Sale Ref: 00000001 DAA: 161158 09465718  
01 FC:148 110.00 CH

The undersigned hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Respectfully Submitted

Date: February 26, 2002



Francis E. Morris


Reg. No. 24,615

PENNIE & EDMONDS LLP

1155 Avenue of the Americas

New York, NY 10036-2711

(650) 493-4935



Express Mail No.: EL 452 482 560 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Dasseux, et al.

Application No.: 09/465,718

Group Art Unit: 1631

Filed: December 17, 1999

Examiner: Borin

For: *Apolipoprotein A-I Agonists and  
Their Use to Treat Dyslipidemic Disorders*

Attorney Docket No.: 9196-018-999

TERMINAL DISCLAIMER


Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

The fee for processing the attached Terminal Disclaimer is believed to be \$110.00. Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is attached for accounting purposes.

Respectfully submitted

Date: February 26, 2002

  
Francis E. Morris Reg. No. 24,615  
PENNIE & EDMONDS LLP  
1155 Avenue of the Americas  
New York, NY 10036-2711  
(650) 493-4935